Revelation Biosciences Q2 FY26 net loss widens 35.97% to $3.32 million

Reuters2026/08/06 20:56

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Revelation Biosciences posted a net loss of $3.32 million for the quarter ended June 30, 2026, widening from $2.44 million a year earlier.
Operating loss widened to $3.66 million as operating expenses climbed 48.8% to $3.66 million versus the prior-year quarter.
Research and development costs rose 45.6% to $1.92 million, driven by higher GEM-AKI program and manufacturing spend, partly offset by lower GEM-CKD expenses.
General and administrative expenses increased 52.5% to $1.74 million, primarily on higher personnel costs including stock-based compensation.
Cash and cash equivalents were $11.5 million at June 30, 2026; the company flagged substantial doubt about its ability to continue as a going concern.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-337967), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Revelation Biosciences Q2 FY26 net loss widens 35.97% to $3.32 million

You may also like

Crypto prices